2022年12月22日

贾里德·怀特洛克特征编辑Taysha基因疗法CEO RA会话II已经辞职后动荡的一年,公司搁置的罕见的疾病管道和面临的批评家庭阻挠计划重启药物项目。会话,他仍将是董事会的成员,将由肖恩·诺兰,董事会主席。更改立即生效,Taysha星期五在一次新闻发布会上说。诺兰说,他计划呼吁加快公司的主要项目和加强最近与阿斯特拉合作,带来了5000万美元。继续阅读端点免费订阅立即解锁这个故事,加入154800 +生物制药专业人士每天阅读端点,它是免费的。注册妮可DeFeudis编辑现代化摘一个新的商业执行从默克公司首席执行官史蒂芬Bancel承诺该公司2023年的一个“更好的地方”Covid-19疫苗交付。尚塔尔Friebertshauser今年1月1日加入现代化作为商业的高级副总裁,在那里她将负责努力在欧洲,中东和加拿大。首席商务官Arpa浏览完——也在默克公司多年被2023年的疫苗合同排队在最近的现代化的第三季度,包括瑞士、科威特和加拿大,更多。阅读更多2022年12月21日36点扎卡里·布伦南高级编辑1月26日,FDA的疫苗adcomm将开会讨论的未来Covid-19加强注射和变异株选择前进,和cb导演彼得·马克昨天预览会议将讨论些什么。二价升压吸收已经停滞,尤其是儿童,标志着现在指向方法来简化这个过程。 The VRBPAC adcomm won’t only look at what the composition of these Covid-19 vaccines should be, and what’s the timing for selecting new strains, but also how often strain selection should take place, he said, noting that the FDA is “trying to get to some sense of normalcy for how we treat vaccinations.” Read More December 21, 2022 09:16 AM ESTUpdated 11:12 AM Zymeworks is capping a rocky year with a committed partner. After announcing it would dole out $50 million to become the second partner on Zymeworks’ HER2 bispecific, Jazz Pharmaceuticals was met with some questions from analysts around the financing engineering of the deal, particularly curious as to why the duo linked up before a crucial readout of the drug, known as zanidatamab. But with a 41.3% objective response rate in a pivotal trial in biliary tract cancer earlier this week, the pair will march forward. Jazz is forking over $325 million to exclusively develop and commercialize zanidatamab in the US, Europe and Japan. If the collaborators make it to the end of the album, the payout could be $1.76 billion for Zymeworks, as well as tiered royalties between 10% and 20% on Jazz’s net sales. BeiGene holds the China, South Korea, Australia and New Zealand rights to the drug. Keep reading Endpoints with a free subscription Unlock this story instantly and join 154,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor With 2022 almost in the rearview mirror, it’s time to look ahead at what to expect in pharma marketing, advertising and drug commercialization strategies for 2023. This year marked the first full year of widely available Covid-19 vaccines — plus multiple treatments and new boosters — and while no one is suggesting the crisis is over, most agree it is at least moving toward an endemic phase. Along with that change also comes a pendulum swing back, at least somewhat, toward pre-pandemic pharma practices. Chief among those is a return to in-person sales rep and medical liaison meetings with healthcare professionals. Premium subscription required